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Under what context do dying b-cells enhance the autoimmune process in type 1 diabetes? Kim et al.
(2007) find that secondary necrosis of b-cells can prime the autoimmune response via uptake by and
activation of antigen-presenting cells through Toll-like receptor 2.The notion that it indeed ‘‘matters how
you die’’ has been investigated by nu-
merous research groups interested in
autoimmune disorders. Cell death may
result in either tolerance or enhanced
autoimmunity, and in type 1 diabetes
(T1D), evidence has been found for
both scenarios. The prevailing thought
is that antigens from cells under attack
can provide new fuel for the autoim-
mune response when they are taken
up by professional antigen-presenting
cells (APCs) in the pancreatic lymph
node, where antigen spreading as well
as targeting of neoantigens occurs.
Conversely, apoptotic b-cell death
can induce tolerance and switch au-
toreactive T cells off. These findings
lead to the hypothesis that ‘‘good’’
apoptotic but not ‘‘bad’’ necrotic cell
death is required for maintaining peace
in the body (Gallucci et al., 1999). How-
ever, it has become increasingly clear
that a simple distinction between good
and bad cell death is difficult to estab-
lish and that the precise degree and
context of cellular demise determines
whether an autoimmune process is
sustained or switched off.
In this issue of Immunity, Kim et al.
(2007) find that apoptotic cells under-
going secondary necrosis, but not
intact apoptotic cells, could induce
tumor necrosis factor (TNF) production
by macrophages and activation of
autoreactive T cells similar to primary
necrotic cells. In addition, secondary
necrotic cells appear to trigger T cell
immunity through a Toll-like recep-
tor 2 (TLR2)-MyD88-NF-kB signaling
pathway. Importantly, autoimmune di-
abetes is markedly inhibited in TLR2-
deficient mice as a consequence of
impaired priming of diabetogenic Tcells by APCs after b-cell injury. The
results presented here thus suggest
that TLR2-dependent stimulation of
APCs by secondary necrotic apoptotic
b-cells may trigger and sustain the
autoaggressive immune response in
autoimmune diabetes. How can we
reconcile the present findings with
previous data implicating TLR2 signal-
ing in enhancing immune regulation
(Zanin-Zhorov et al., 2006) and, more
importantly, with a previous report
(Hugues et al., 2002) demonstrating
that a limited degree of b-cell apo-
ptosis can decrease the incidence of
type 1 diabetes in nonobese diabetic
(NOD) mice?
To better understand the dilemma of
whether target cell death will fuel or
quench the autoimmune response, it
is important to consider several fac-
tors: First is the degree of apoptosis
and manner of cell death. On the basis
of the present report and previous
evidence, the emerging theme is that
secondary necrotic cell death renders
induction of autoimmune immune
responses more likely because APCs
are more efficiently primed, possibly
by recognizing damage-associated
molecular patterns (DAMPs) (Gallucci
et al., 1999). In addition, it appears that
only limited apoptosis has to occur in
order for tolerance to be achieved
(Hugues et al., 2002).
The second factor is the precise tim-
ing of cell death in relation to the stage
of the autoimmune response. Hugues
et al. (2002) gave 40 mg/kg streptozo-
tocin to 4-week-old NOD mice and
prevented T1D in greater than 50% of
the animals. In contrast, when admin-
istering the same drug to older NOD
mice, Kim et al. (2007) found TLR2-Immunitydependent acceleration of the dis-
ease. On the basis of these findings,
it is reasonable to hypothesize that
the precise degree of pre-existing in-
flammation and islet destruction will
determine the likelihood for apoptotic
b-cells to induce tolerance. In this con-
text, the presence of other inflamma-
tory factors such as TNF, interferons,
and possibly certain TLR ligands
should be considered.
Third, the precise balance between
regulatory (Treg) and effector T cells
will probably determine which cell
population is more efficiently primed
by APCs that engulf and present auto-
antigens. It is clear that the state of
the APCs is a major factor determining
whether Treg or effector T cells are
primed or whether their anergy or
deletion occurs. In this respect, many
inflammatory mediators are also re-
quired for maintaining regulatory cells
and may constitute important factors
for curbing the effector response
through apoptosis (Figure 1 and Dis-
cussion below). Thus, the number
and location of effector T cells versus
Treg cells reactive to islet antigens,
as well as their likelihood to encounter
APCs that are in a tolergoneic or acti-
vating state, will in the end determine
whether prevention or enhancement
of autoimmunity occurs.
Interestingly, in recent reports it has
become clear that inflammatory fac-
tors such as TNF, interferons, or TLR2
ligands can paradoxically reduce in-
flammation through the selective in-
duction of Treg cells or by enhancing
apoptosis of effector cells. Conversely,
certain factors with known regulatory
function such as TGF-b have dual ef-
fects and can in some cases enhance27, August 2007 ª2007 Elsevier Inc. 183
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Previewsinflammation. Thus, several reports
have shown that TLR2 might be crucial
for the activation and maintenance of
Treg cells. This is evidenced not only
in the mouse from studies involving
TLR2-deficient animals or TLR2 ago-
nists in vitro (Sutmuller et al., 2006)
but also in human type 1 diabetes
from studies involving hsp277, a heat-
shock-protein-derived peptide that
induces tolerance in this disease
(Zanin-Zhorov et al., 2006). All these
studies point to a role for TLR2 in its
capacity to enhance Treg cells prolif-
eration, which can occur even under
inflammatory conditions. We do not
understand the difference in function
compared with the present report but
can hypothesize that the timing and
degree of TLR2 engagement may be
crucial. In addition, presence in the
microenvironment of particular APC
types and inflammatory mediators, for
example as a consequence of micro-
bial infection, will probably have crucial
influence on the outcome of TLR liga-
tion in autoimmunity.
TNF is an interesting molecule that
can be important for controlling (Wu
et al., 2002) as well as priming Treg
cells (Chen et al., 2007). TNF can en-
hance inflammation and autoimmune
diabetes when present early during di-
abetogenesis, but it also switches off
effector cells and prevents diabetes by
inducing apoptosis when it is present
at later stages (Christen et al., 2001).
On the basis of these observations, it
might be extremely difficult, if not im-
possible, to alter TNF signaling path-
ways in type 1 diabetes therapeuti-
cally. Yet, it is of interest to mention
here that multifaceted effects can be
strictly disease dependent. Thus, in
some cases, for example in arthritis
where TNF predominantly enhances
inflammation and curbs Treg cell activ-
ity, this cytokine is suitable as a thera-
peutic target.
Last, it is noteworthy to point out
that TGF-b, which has been portrayed
as a hallmark regulatory cytokine be-
cause of its role in the development
and function of Foxp3+ Treg cells, is
now known to exhibit dual functions
as well. Its effects are context depen-
dent, with IL-6 conferring TGF-b a
crucial role in differentiating IL-17-pro-
Figure 1. Induction or Abrogation of Type 1 Diabetes under Inflammatory Conditions
Kim et al. (2007) observe that secondary necrosis of b-cells can prime the autoimmune response in
type 1 diabetes by activating APCs through TLR2. Ensuing TNF production by these cells induces
the activation of autoreactive T cells that cause diabetes. Current understanding suggests a dual
role of TLR2 and proinflammatory cytokines such as TNF in autoimmunity. Engagement of TLR2
on Treg cells or APCs, for example during a microbial infection (which may in some cases also
cause b-cell death), can induce the proliferation of Treg cells and enhance their capacity to control
pathogenic effector T cells. Similarly, TNF, and possibly other proinflammatory cytokines, can
have a beneficial role in autoimmune diabetes by stimulating Treg cell expansion and function
or by inducing apoptosis of autoreactive T cells.184 Immunity 27, August 2007 ª2007 Elsevier Inc.ducing cells that can have destructive
effects in autoimmunity (Bettelli et al.,
2006).
For type 1 diabetes and probably
other autoimmune disorders, our chal-
lenge in the future will be to precisely
model and understand the balance
of effector and regulatory cells and
their location in context with the devel-
opment of b-cell destruction. As dis-
cussed here, most factors such as
TNF, interferons, and certain TLR li-
gands can have positive as well as
negative effects on the evolving auto-
immune response depending on how
efficiently they activate the existing
Treg cell compartment, how many ef-
fector T cells they induce, and how
much apoptosis of these effector cells
ensues. The type, number, and activa-
tion state of APCs in the pancreatic
lymph node is also important to con-
sider, and the reality might be that at
any given time, APCs with tolerogenic
versus immunogenic phenotypes are
present. A recently developed tool
might be of help in guiding our experi-
mentation and better interpreting our
findings: the virtual NOD mouse
(Zheng et al., 2007). This model can
illustrate unexpected yet important
aspects of the autoimmune response
in T1D, for example the accumulation
of Treg cells that are in the islets of
mice with advanced diabetes and
that appear to be unable to control
effector T cells. Ultimately, such mod-
eling will allow immunological profiling
on a per-animal basis and more tar-
geted deployment of immune-based
interventions that aim at reducing
effector T cells or enhancing Treg
cells. This will be instrumental for all
factors that have been shown to have
opposing effects on the autoimmune
process depending on the immuno-
logical context (b-cell death, TLRs,
TNF, interferons, and more recently
TGF-b). Until we have reached this de-
gree of insight, we will be well advised
to focus interventions on factors that
appear to have more uniform effects
in tolerizing the immune system. These
include IL-10 and IL-4 induction,
mucosal antigen administration, and
the use of short-term courses of sys-
temic immunosuppressants for paving




Bettelli, E., Carrier, Y., Gao, W., Korn, T.,
Strom, T.B., Oukka, M., Weiner, H.L., and
Kuchroo, V.K. (2006). Nature 441, 235–238.
Chen, X., Baumel, M., Mannel, D.N., Howard,
O.M., and Oppenheim, J.J. (2007). J. Immunol.
179, 154–161.
Christen, U., Wolfe, T., Mohrle, U., Hughes,
A.C., Rodrigo, E., Green, E.A., Flavell, R.A.,
and von Herrath, M.G. (2001). J. Immunol.
166, 7023–7032.The Expanding U
of Regulatory T C
Thomas F. Gajewski1,*
1University of Chicago, Chicago, IL 60637,
*Correspondence: tgajewsk@medicine.bsd
DOI 10.1016/j.immuni.2007.08.001
Evidence has indicated that failed
nisms within the tumor microenvi
by describing tumor-infiltrating g
Substantial evidence has been ac-
cumulated indicating that immuno-
suppressive mechanisms within the
solid-tumor microenvironment provide
a major barrier to effective antitumor
immunity. One such mechanism ap-
pears to be through the accumula-
tion of CD4+CD25+Foxp3+ regulatory
T (Treg) cells. Treg cells have been
shown to be present at increased
numbers in both the peripheral blood
and among the tumor-infiltrating lym-
phocyte (TIL) population in both mu-
rine models and in patients with any
of several histologies of cancer. Mech-
anistically, murine models of Treg cell
depletion (usually with CD25 mono-
clonal antibody) have demonstrated
improved immune-mediated tumor
control, arguing that they are function-
ally important. Their role directly within
the tumor microenvironment is sup-
ported by experiments in which anti-
CD25 was injected directly into the
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d T cells that have regulatory func
that Treg cells can suppress the cyto-
lytic activity of activated CD8+ T cells
in a target tissue through an indirect
mechanism that prevents lysis but
not conjugate formation with target
cells (Mempel et al., 2006). Both natu-
ral thymically derived Treg cells and
peripherally induced Treg cells have
been implicated in tumor models, the
latter of which is consistent with the
high amounts of transforming growth
factor b (TGF-b) observed to be pro-
duced in the tumor microenvironment.
Although there are not yet definitive
mechanistic data showing improved
clinical response with Treg cell deple-
tion in human cancer patients, one
study has shown a greater induction
of antitumor effector T cells when
Treg cell numbers were reduced by
the administration of a CD25-targeted
toxin (Dannull et al., 2005).
However,whetherCD4+CD25+FoxP3+
Treg cells represent the only lympho-
cyte population involved in suppress-
ing effector T cell function within the
tumor microenvironment is not clear.
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tion.
A role for B cells in suppressing T cell-
dependent tumor rejection has been
identified in several murine model sys-
tems (Qin et al., 1998). Interleukin10
(IL-10)-producing CD8+ T cells, and
CD4CD8 T cells, also have been
identified (Shevach, 2006) that appear
to inhibit the activation of conventional
CD8+ T cells in the tumor context. In
this issue of Immunity, Peng et al.
(2007) provide convincing evidence
that gd T cell receptor (TCR)-express-
ing T cells derived from the tumor
microenvironment can have potent
suppressive activity toward conven-
tional T cells both in vitro and in vivo,
an observation that could have impor-
tant clinical relevance.
gd T cells have been implicated as
participants in multiple facets of anti-
tumor immune responses, predomi-
nantly as positive regulators. In murine
studies in vivo, gd T cells were found to
be recruited to tumor sites rapidly,
appearing before ab T cells and pro-
ducing high amounts of interferon-g
(IFN-g). Deficiency of gd T cells
27, August 2007 ª2007 Elsevier Inc. 185
